1233181-87-7

Upstream product

• 1233094-95-5 7-bromo-2-methylsulfanyl-pyrrolo[2,1-f][1,2,4]triazine 
• 5720-06-9 2-Methoxyphenylboronic acid 

Downstream Products

• 1232816-20-4 7-(2-methoxyphenyl)-2-(methylsulfinyl)pyrrolo[2,1-f][1,2,4]triazine 
• 1232816-03-3 5,6-dibromo-7-(2-methoxy-phenyl)-2-methylsulfanyl-pyrrolo[2,1-f][1,2,4]triazine 
• 1232399-14-2 [2-methoxy-4-(4-(morpholin-4-yl)-piperidin-1-yl)-phenyl]-[7-(2-methoxy-phenyl)-pyrrolo[2,1-f][1,2,4]triazin-2-yl]-amine 
• 1233144-10-9 (S)-1-(4-{3-methoxy-4-[7-(2-methoxy-phenyl)-pyrrolo[2,1-f][1,2,4]triazin-2-ylamino]-phenyl}-piperazin-1-yl)-propan-2-ol 
• 1233144-12-1 (R)-1-(4-{3-methoxy-4-[7-(2-methoxy-phenyl)-pyrrolo[2,1-f][1,2,4]triazin-2-ylamino]-phenyl}-piperazin-1-yl)-propan-2-ol 
• 1232398-41-2 (4-methoxy-phenyl)-[7-(2-methoxy-phenyl)-pyrrolo[2,1-f][1,2,4]triazin-2-yl]-amine 
• 1232814-59-3 C₂₇H₃₁N₅O₂ 
• 1232399-45-9 {4-[7-(2-methoxy-phenyl)-pyrrolo[2,1-f][1,2,4]triazin-2-ylamino]-phenyl}-morpholin-4-yl-methanone 
• 1232812-47-3 C₂₁H₂₁N₅O₃S 
• 1233185-21-1 C₁₄H₁₃N₃O₃S 
• 1232784-37-0 C₁₃H₁₁N₃O₂ 
• 1233142-16-9 C₁₄H₁₀F₃N₃O₄S 
• 1232399-64-2 C₂₃H₂₃N₅O₂ 
• 1232398-89-8 (S)-1-(4-{4-[7-(2-methoxy-phenyl)-pyrrolo[2,1-f][1,2,4]triazin-2-ylamino]-phenyl}-piperazin-1-yl)-propan-2-ol 

Relevant academic research and scientific papers

2,7-Disubstituted-pyrrolo[2,1- f ][1,2,4]triazines: New variant of an old template and application to the discovery of anaplastic lymphoma kinase (ALK) inhibitors with in vivo antitumor activity

A novel 2,7-disubstituted-pyrrolo[2,1-f][1,2,4]triazine scaffold has been designed as a new kinase inhibitor platform mimicking the bioactive conformation of the well-known diaminopyrimidine motif. The design, synthesis, and validation of this new pyrrolo[2,1-f][1,2,4]triazine scaffold will be described for inhibitors of anaplastic lymphoma kinase (ALK). Importantly, incorporation of appropriate potency and selectivity determinants has led to the discovery of several advanced leads that were orally efficacious in animal models of anaplastic large cell lymphoma (ALCL). A lead inhibitor (30) displaying superior efficacy was identified and in depth in vitro/in vivo characterization will be presented.

2,7-Pyrrolo[2,1-f][1,2,4]triazines as JAK2 inhibitors: Modification of target structure to minimize reactive metabolite formation

The JAK2/STAT pathway has important roles in hematopoiesis. With the discovery of the JAK2 V617F mutation and its presence in many patients with myeloproliferative neoplasms, research in the JAK2 inhibitor arena has dramatically increased. We report a nov

PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS

The present invention provides a compound of formula (I) or a salt form thereof, wherein Q1, Q2, Q3, and Q4 are as defined herein. The compound of formula (I) has ALK and/or JAK2 inhibitory activity, and may be used to treat proliferative disorders.